{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:30:40Z","timestamp":1793712640668,"version":"4.6.1"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.25190","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T21:47:54Z","timestamp":1607464074000},"page":"e2025190","source":"Crossref","is-referenced-by-count":20,"title":["Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women"],"prefix":"10.1001","volume":"3","author":[{"given":"Monika A.","family":"Izano","sequence":"first","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan C.","family":"Lo","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette L.","family":"Adams","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Ettinger","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Ott","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini","family":"Chandra","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita L.","family":"Hui","sequence":"additional","affiliation":[{"name":"Pharmacy Outcomes Research Group, Kaiser Permanente California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Niu","sequence":"additional","affiliation":[{"name":"Pharmacy Outcomes Research Group, Kaiser Permanente California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie H.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain S.","family":"Neugebauer","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"issue":"10","key":"zoi200825r1","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s guide to prevention and treatment of osteoporosis.","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"issue":"2","key":"zoi200825r2","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.amjmed.2008.12.003","article-title":"Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.","volume":"122","author":"Bilezikian","year":"2009","journal-title":"Am J Med"},{"issue":"1","key":"zoi200825r3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research.","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"22","key":"zoi200825r4","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMp1202619","article-title":"Bisphosphonates for osteoporosis\u2014where do we go from here?","volume":"366","author":"Whitaker","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi200825r5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.v27.2","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"24","key":"zoi200825r6","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"zoi200825r7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis.","volume":"75","author":"Mellstr\u00f6m","year":"2004","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"zoi200825r8","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1111\/jgs.2017.65.issue-9","article-title":"Long-term oral bisphosphonate therapy and fractures in older women: the Women\u2019s Health Initiative.","volume":"65","author":"Drieling","year":"2017","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"zoi200825r9","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1097\/GME.0000000000000757","article-title":"Long-term bisphosphonates: primum non nocere.","volume":"23","author":"Ott","year":"2016","journal-title":"Menopause"},{"issue":"2","key":"zoi200825r10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","article-title":"Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012.","volume":"57","author":"Wysowski","year":"2013","journal-title":"Bone"},{"issue":"1","key":"zoi200825r11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00198-012-1938-5","article-title":"Ten-year hip fracture incidence rate trends in a large California population, 1997-2006.","volume":"24","author":"Adams","year":"2013","journal-title":"Osteoporos Int"},{"issue":"3","key":"zoi200825r12","first-page":"188","article-title":"Fracture risk tool validation in an integrated healthcare delivery system.","volume":"17","author":"Lo","year":"2011","journal-title":"Am J Manag Care"},{"issue":"3","key":"zoi200825r13","first-page":"e206","article-title":"Trends in mortality following hip fracture in older women.","volume":"21","author":"Lo","year":"2015","journal-title":"Am J Manag Care"},{"issue":"9","key":"zoi200825r14","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s00198-014-2750-1","article-title":"Racial\/ethnic differences in hip and diaphyseal femur fractures.","volume":"25","author":"Lo","year":"2014","journal-title":"Osteoporos Int"},{"issue":"6","key":"zoi200825r15","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s00198-006-0085-2","article-title":"Persistence with weekly alendronate therapy among postmenopausal women.","volume":"17","author":"Lo","year":"2006","journal-title":"Osteoporos Int"},{"issue":"7","key":"zoi200825r16","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/jbmr.3420","article-title":"Bisphosphonate drug holiday and fracture risk: a population-based cohort study.","volume":"33","author":"Adams","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"2","key":"zoi200825r17","first-page":"197","article-title":"Determinants of oral bisphosphonate use beyond 5 years.","volume":"26","author":"Izano","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"zoi200825r18","first-page":"719","article-title":"Using pharmacy data and adherence to define long-term bisphosphonate exposure in women.","volume":"25","author":"Izano","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"zoi200825r19","first-page":"503","article-title":"Predicting adherence and persistence with oral bisphosphonate therapy in an integrated health care delivery system.","volume":"23","author":"Hui","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"zoi200825r20","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1210\/jc.2008-0926","article-title":"A revised clinician\u2019s guide to the prevention and treatment of osteoporosis.","volume":"93","author":"Dawson-Hughes","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"zoi200825r21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jocd.2008.04.003","article-title":"National Osteoporosis Foundation 2008 clinician\u2019s guide to prevention and treatment of osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist.","volume":"11","author":"Watts","year":"2008","journal-title":"J Clin Densitom"},{"issue":"6","key":"zoi200825r23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"zoi200825r24","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/sim.v39.11","article-title":"Propensity scores using missingness pattern information: a practical guide.","volume":"39","author":"Blake","year":"2020","journal-title":"Stat Med"},{"issue":"1","key":"zoi200825r25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward.","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"issue":"1","key":"zoi200825r26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/0962280208092345","article-title":"Observation plans in longitudinal studies with time-varying treatments.","volume":"18","author":"Hern\u00e1n","year":"2009","journal-title":"Stat Methods Med Res"},{"key":"zoi200825r27","doi-asserted-by":"crossref","DOI":"10.1111\/biom.13271","article-title":"Exploiting nonsystematic covariate monitoring to broaden the scope of evidence about the causal effects of adaptive treatment strategies.","author":"Kreif","year":"2020","journal-title":"Biometrics"},{"issue":"4","key":"zoi200825r28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","article-title":"Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry.","volume":"16","author":"Schousboe","year":"2013","journal-title":"J Clin Densitom"},{"issue":"8","key":"zoi200825r29","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"2","key":"zoi200825r30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2202\/1557-4679.1212","article-title":"When to start treatment? a systematic approach to the comparison of dynamic regimes using observational data.","volume":"6","author":"Cain","year":"2010","journal-title":"Int J Biostat"},{"issue":"5","key":"zoi200825r32","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology.","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"issue":"6","key":"zoi200825r33","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models.","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"1","key":"zoi200825r34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/0962280210386207","article-title":"Diagnosing and responding to violations in the positivity assumption.","volume":"21","author":"Petersen","year":"2012","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"zoi200825r35","doi-asserted-by":"crossref","DOI":"10.1515\/1557-4679.1370","article-title":"Targeted minimum loss based estimation of causal effects of multiple time point interventions.","volume":"8","author":"van der Laan","year":"2012","journal-title":"Int J Biostat"},{"issue":"16","key":"zoi200825r37","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1002\/sim.v38.16","article-title":"Targeted learning with daily EHR data.","volume":"38","author":"Sofrygin","year":"2019","journal-title":"Stat Med"},{"issue":"1","key":"zoi200825r38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios.","volume":"21","author":"Hern\u00e1n","year":"2010","journal-title":"Epidemiology"},{"issue":"9041","key":"zoi200825r39","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"24","key":"zoi200825r40","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"issue":"1","key":"zoi200825r41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"issue":"2","key":"zoi200825r42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience.","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"issue":"5","key":"zoi200825r43","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.","volume":"25","author":"Schwartz","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"12","key":"zoi200825r44","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1007\/s00198-017-4215-9","article-title":"Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.","volume":"28","author":"Mignot","year":"2017","journal-title":"Osteoporos Int"},{"issue":"5","key":"zoi200825r45","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/MLR.0000000000001294","article-title":"Duration of bisphosphonate drug holidays and associated fracture risk.","volume":"58","author":"Curtis","year":"2020","journal-title":"Med Care"},{"key":"zoi200825r46","doi-asserted-by":"publisher","first-page":"i3365","DOI":"10.1136\/bmj.i3365","article-title":"Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study.","volume":"353","author":"Abrahamsen","year":"2016","journal-title":"BMJ"},{"issue":"8","key":"zoi200825r47","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"zoi200825r48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1515\/ijb-2015-0028","article-title":"A case study of the impact of data-adaptive versus model-based estimation of the propensity scores on causal inferences from three inverse probability weighting estimators.","volume":"12","author":"Neugebauer","year":"2016","journal-title":"Int J Biostat"},{"key":"zoi200825r22","unstructured":"FRAX Fracture Risk Assessment Tool. Welcome to FRAX. Accessed October 30, 2020. http:\/\/www.shef.ac.uk\/FRAX\/"},{"key":"zoi200825r31","unstructured":"Robins? JM. Marginal structural models. In: 1997 Proceedings of the American Statistical Association, Section on Bayesian Statistical Science. American Statistical Association; 1998:1-10. Accessed October 30, 2020. https:\/\/cdn1.sph.harvard.edu\/wp-content\/uploads\/sites\/343\/2013\/03\/msm-web.pdf"},{"key":"zoi200825r36","unstructured":"Leong? TK, Tabada? GH, Yang? J, Zhu? Z, Neugebauer? R; Kaiser Permanente Northern California Division of Research. MSMstructure. Updated March 2017. Accessed November 4, 2020. https:\/\/divisionofresearch.kaiserpermanente.org\/projects\/biostatistics\/causalinferencesoftware"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2773774\/izano_2020_oi_200825_1606772851.49195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T21:12:14Z","timestamp":1618607534000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2773774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.25190","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,7]]}}}